ESI-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
=== Surgery === Surgery (thyroidectomy to remove the whole thyroid or a part of it) is not extensively used because most common forms of hyperthyroidism are quite effectively treated by the radioactive iodine method, and because there is a risk of also removing the parathyroid glands, and of cutting the recurrent laryngeal nerve, making swallowing difficult, and even simply generalized staphylococcal infection as with any major surgery. Some people with Graves' may opt for surgical intervention. This includes those who cannot tolerate medicines for one reason or another, people who are allergic to iodine, or people who refuse radioiodine. A 2019 systematic review concluded that the available evidence shows no difference between visually identifying the nerve or utilizing intraoperative neuroimaging during surgery, when trying to prevent injury to the recurrent laryngeal nerve during thyroid surgery. If people have toxic nodules, treatments typically include either the removal or injection of the nodule with alcohol.
=== DAPI === DAPI is a fluorescent nuclear stain, excited by ultraviolet light and showing strong blue fluorescence when bound to DNA. DAPI binds with A=T rich repeats of chromosomes. DAPI is also not visible with regular transmission microscopy. It may be used in living or fixed cells. DAPI-stained cells are especially appropriate for cell counting.
== Cause == Beriberi is often caused by eating a diet with a very high proportion of calorie-rich white rice (common in Asia) or cassava root (common in sub-Saharan Africa), without much if any thiamine-containing animal products or vegetables. It may also be caused by shortcomings other than inadequate intake – diseases or operations on the digestive tract, alcoholism, dialysis or genetic deficiencies. All those causes mainly affect the central nervous system, and provoke the development of Wernicke's encephalopathy. Wernicke's disease is one of the most prevalent neurological or neuropsychiatric diseases. In autopsy series, features of Wernicke lesions are observed in approximately 2% of general cases. Medical record research shows that about 85% had not been diagnosed, although only 19% would be asymptomatic. In children, only 58% were diagnosed. In alcohol abusers, autopsy series showed neurological damages at rates of 12.5% or more. Mortality caused by Wernicke's disease reaches 17% of diseases, which means 3.4/1000 or about 25 million contemporaries. The number of people with Wernicke's disease may be even higher, considering that early stages may have dysfunctions prior to the production of observable lesions at necropsy. In addition, uncounted numbers of people can experience fetal damage and subsequent diseases.
Sources: en.wikipedia.org
Based on a study conducted by the Department of Family Medicine at the Oregon Health and Science University the use of BMP increased rapidly, from 5.5% of fusion cases in 2003 to 28.1% of fusion cases in 2008. BMP use was greater among patients with previous surgery and among those having complex fusion procedures (combined anterior and posterior approach, or greater than 2 disc levels). Major medical complications, wound complications, and 30-day rehospitalization rates were nearly identical with or without BMP. Reoperation rates were also very similar, even after stratifying by previous surgery or surgical complexity, and after adjusting for demographic and clinical features. On average, adjusted hospital charges for operations involving BMP were about $15,000 more than hospital charges for fusions without BMP, though reimbursement under Medicare's Diagnosis-Related Group system averaged only about $850 more. Significantly fewer patients receiving BMP were discharged to a skilled nursing facility.
As a rule, only the external female genitals of placental mammals are referred to as the "vulva", although the term is also used in the scientific literature for functionally comparable structures in other animal groups such as marsupials and roundworms (Nematoda). For comparison, birds, reptiles, amphibians, and monotremes have a cloaca. An organ system that resembles a vulva does not exist for these animals. The vulva of a placental consists of the following along with its variations:
Helium is the second least reactive noble gas after neon, and thus the second least reactive of all elements. It is chemically inert and monatomic in all standard conditions. Because of helium's relatively low molar (atomic) mass, its thermal conductivity, specific heat, and sound speed in the gas phase are all greater than any other gas except hydrogen. For these reasons and the small size of helium monatomic molecules, helium diffuses through solids at a rate three times that of air and around 65% that of hydrogen. Helium is the least water-soluble monatomic gas, and one of the least water-soluble of any gas (CF4, SF6, and C4F8 have lower mole fraction solubilities: 0.3802, 0.4394, and 0.2372 x2/10−5, respectively, versus helium's 0.70797 x2/10−5), and helium's index of refraction is closer to unity than that of any other gas. Helium has a negative Joule–Thomson coefficient at normal ambient temperatures, meaning it heats up when allowed to freely expand. Only below its Joule–Thomson inversion temperature (of about 32 to 50 K (−241.2 to −223.2 °C; −402.1 to −369.7 °F) at one atm (0.10 MPa)) does it cool upon free expansion. Once precooled below this temperature, helium can be liquefied through expansion cooling. Most extraterrestrial helium is plasma in stars, with properties quite different from those of atomic helium. In a plasma, helium's electrons are not bound to its nucleus, resulting in very high electrical conductivity, even when the gas is only partially ionized. The charged particles are highly influenced by magnetic and electric fields.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.